Cough

Respiratory
11
Pipeline Programs
6
Companies
13
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
8 programs
6
2
BLU-5937Phase 31 trial
BLU-5937Phase 31 trial
BLU-5937Phase 11 trial
BLU-5937 IRPhase 11 trial
CamlipixantPhase 11 trial
+3 more programs
Active Trials
NCT03638180Completed90Est. Oct 2018
NCT05570539Completed30Est. Jul 2024
NCT05899829Completed42Est. Aug 2023
+5 more trials
BioCryst Pharmaceuticals
1 program
1
Peramivir+SOCPhase 31 trial
Active Trials
NCT00958776Terminated405Est. Oct 2013
Sanofi
SanofiPARIS, France
1 program
1
Ambroxol HydrochloridePhase 21 trial
Active Trials
NCT03415269Completed14Est. Apr 2018
UP
UCB PharmaBelgium - Brussels
1 program
1
levocetirizine dihydrochloridePhase 21 trial
Active Trials
NCT00520754Completed15Est. Mar 2003
Stuart Therapeutics
1 program
Adenosine TriphosphateN/A1 trial
Active Trials
NCT03722849CompletedEst. May 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Clinical Evaluation of QFlu Combo TestN/A1 trial
Active Trials
NCT01506583CompletedEst. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GSKBLU-5937
GSKBLU-5937
BioCryst PharmaceuticalsPeramivir+SOC
SanofiAmbroxol Hydrochloride
UCB Pharmalevocetirizine dihydrochloride
GSKGSK5464714- Camlipixant
GSKCamlipixant
GSKCamlipixant
GSKCamlipixant
GSKBLU-5937 IR
GSKBLU-5937
Stuart TherapeuticsAdenosine Triphosphate
Allergy TherapeuticsClinical Evaluation of QFlu Combo Test

Clinical Trials (13)

Total enrollment: 2,487 patients across 13 trials

NCT05600777GSKBLU-5937

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Start: Dec 2022Est. completion: Mar 2027975 patients
Phase 3Recruiting
NCT05599191GSKBLU-5937

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Start: Oct 2022Est. completion: May 2026825 patients
Phase 3Active Not Recruiting
NCT00958776BioCryst PharmaceuticalsPeramivir+SOC

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Start: Nov 2009Est. completion: Oct 2013405 patients
Phase 3Terminated
NCT03415269SanofiAmbroxol Hydrochloride

A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.

Start: Feb 2018Est. completion: Apr 201814 patients
Phase 2Completed
NCT00520754UCB Pharmalevocetirizine dihydrochloride

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

Start: Dec 2001Est. completion: Mar 200315 patients
Phase 2Completed
NCT06497517GSKGSK5464714- Camlipixant

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Start: Jul 2024Est. completion: Aug 202414 patients
Phase 1Completed
NCT06222892GSKCamlipixant

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

Start: Feb 2024Est. completion: Dec 202432 patients
Phase 1Completed
NCT05959447GSKCamlipixant

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

Start: Jul 2023Est. completion: Oct 202345 patients
Phase 1Completed
NCT05899829GSKCamlipixant

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

Start: Jun 2023Est. completion: Aug 202342 patients
Phase 1Completed
NCT05570539GSKBLU-5937 IR

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Start: Oct 2022Est. completion: Jul 202430 patients
Phase 1Completed
NCT03638180GSKBLU-5937

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Start: Jul 2018Est. completion: Oct 201890 patients
Phase 1Completed
NCT03722849Stuart TherapeuticsAdenosine Triphosphate

Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients

Start: Mar 2019Est. completion: May 2022
N/ACompleted
NCT01506583Allergy TherapeuticsClinical Evaluation of QFlu Combo Test

Clinical Evaluation of QFlu Combo Test

Start: Nov 2010Est. completion: May 2012
N/ACompleted

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,487 patients
6 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)